Sign in
4

Changes in Ownership

Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001273351-26-000004

CHIEF ACCOUNTING OFFICER sold 43,682 shares at an average $81.49 ($3,559,495)

  • CHIEF ACCOUNTING OFFICER acquired 43,682 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
CARR EDWARD CHIEF ACCOUNTING OFFICER 2026-03-12 Option exercise 10b5-1 +16,182 $17.88 $289,334 16,182 D: show line 1 in the form
CARR EDWARD CHIEF ACCOUNTING OFFICER 2026-03-12 Option exercise 10b5-1 +17,500 $22.07 $386,225 33,682 D: show line 2 in the form
CARR EDWARD CHIEF ACCOUNTING OFFICER 2026-03-12 Option exercise 10b5-1 +10,000 $21.77 $217,700 43,682 D: show line 3 in the form
CARR EDWARD CHIEF ACCOUNTING OFFICER 2026-03-12 Sale 10b5-1 −15,852 $80.71 $1,279,415 27,830 D: show line 4 in the form
CARR EDWARD CHIEF ACCOUNTING OFFICER 2026-03-12 Sale 10b5-1 −23,465 $81.75 $1,918,264 4,365 D: show line 5 in the form
CARR EDWARD CHIEF ACCOUNTING OFFICER 2026-03-12 Sale 10b5-1 −3,865 $82.66 $319,481 500 D: show line 6 in the form
CARR EDWARD CHIEF ACCOUNTING OFFICER 2026-03-12 Sale 10b5-1 −200 $83.38 $16,676 300 D: show line 7 in the form
CARR EDWARD CHIEF ACCOUNTING OFFICER 2026-03-12 Sale 10b5-1 −300 $85.53 $25,659 0 D: show line 8 in the form
Open-market sales · 43,682 sh · avg $81.49 · $3,559,495

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
CARR EDWARD CHIEF ACCOUNTING OFFICER 2026-03-12 Option exercise · Stock Option (Right to Buy) 10b5-1 −16,182 63,818 D: show line 9 in the form
CARR EDWARD CHIEF ACCOUNTING OFFICER 2026-03-12 Option exercise · Stock Option (Right to Buy) 10b5-1 −17,500 42,500 D: show line 10 in the form
CARR EDWARD CHIEF ACCOUNTING OFFICER 2026-03-12 Option exercise · Stock Option (Right to Buy) 10b5-1 −10,000 50,000 D: show line 11 in the form
Loading xslF345X05/ownership.xml…